Clinical characteristics and transfusion strategies of delayed serological transfusion reactions caused by platelet transfusion in tumor patients

Abstract

Objective To analyze the clinical manifestations of delayed serological transfusion reactions (DSTR) after platelet transfusion in tumor patients, and to explore the transfusion strategy. Methods Clinical data and laboratory test results of patients with positive antibody screening were analyzed after platelet transfusion in our hospital from January 1, 2015 to June 30, 2023, and the incidence rate, clinical characteristics and transfusion strategy of patients with DSTR were analyzed. Results A total of 2 553 patients with 6 057 platelet transfusions were reviewed. Eight patients developed DSTR and received a total of 21 therapeutic amounts of platelets, and 5 patients were subsequently transfused with red blood cells. Rh system antibodies were detected in 7 cases (4 anti-E, 1 anti-c/E, 1 anti-C and 1 anti-c) and Kell system antibodies in 1 case. Conclusion Tumor patients may also develop DSTR after platelet transfusion. It is necessary to pay close attention to the antibody situation and perform matched transfusion when transfusing blood again.

Keywords

• tumor patients
• platelet transfusion
• delayed serological transfusion reactions(dstr)